Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melissa Journot

Podiatrist, Foot & Ankle Surgery Leawood, KS Doctor of Podiatric Medicine

NPI 1497106330 CMS profile 2210754

4801 College Blvd, Leawood, KS 66211

Open in the dashboard

General payments

$25,901

295 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Journot of Leawood, KS is reported in the CMS Open Payments database as having received $25,901 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,488 32
2024 General $748 20
2023 General $9,613 101
2022 General $5,625 58
2021 General $5,579 52
2020 General $1,873 15
2019 General $975 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Journot
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Melissa Journot were reported at $1,488. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Melissa Journot Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $975 $389 $118–$1,406 $163
2020 $1,873 $191 $62–$691 $114
2021 $5,579 $329 $104–$1,341 $132
2022 $5,625 $419 $125–$1,611 $149
2023 $9,613 $377 $128–$1,164 $160
2024 $748 $394 $134–$1,168 $164
2025 $1,488 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $6,134 76 payments
  2. Arthrex, Inc. $2,025 13 payments
  3. Electronic Waveform Lab, Inc. $1,979 25 payments
  4. Medical Device Business Services, Inc. $1,505 8 payments
  5. Paragon 28, Inc. $1,322 3 payments
  6. Bioventus LLC $1,145 12 payments
  7. In2Bones USA, LLC $1,116 3 payments
  8. Titan Surgical Group, LLC $1,018 2 payments
  9. Tenex Health Inc. $937 7 payments
  10. Medline Industries, Inc. $907 8 payments
  11. Other $7,814 138 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,203 265 payments
  2. Travel and Lodging $7,326 25 payments
  3. Education $2,362 4 payments
  4. Gift $10 1 payment
Products named General payments · program years 2019–2025
  1. MEDLINE UNITE $2,590 20 payments
  2. INBONE $1,849 20 payments
  3. INFINITY $1,055 12 payments
  4. CoLink $1,021 2 payments
  5. Product Portfolio $980 2 payments
  6. PROPHECY $933 12 payments
  7. Kerecis Omega3 SurgiClose $717 4 payments
  8. Stimrouter Implantable Kit $609 2 payments
  9. Kerecis Omega3 GraftGuide $599 2 payments
  10. PROSTEP $570 2 payments
  11. Other $15,512 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

194

Median for Podiatry: 160

Drug cost

$1,701

Median for Podiatry: $2,368

Branded share of claims

18%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $501
Oxycodone Hcl Generic 54 $454
Terbinafine Hcl Generic 17 $226
Cyclobenzaprine Hcl Generic 21 $172
Prednisone Generic 17 $101
Methylprednisolone Generic 16 $94
Ibuprofen Generic 11 $80
Gabapentin Generic 11 $51
Meloxicam Generic 12 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$71,734

Of which drugs: $7,871

Medicare patients

233

Average age 74

Services billed

991

131 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Diabetes 42%
Depression 32%
Ischemic heart disease 29%
Chronic kidney disease 27%
Atrial fibrillation 21%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 73 $45
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 19 77 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kimyrsa
  • Melinta Therapeutics, Inc. $8
$8 — —
Orbactiv
  • Melinta Therapeutics, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record